

# Poly-L-Lactic Acid as a Biomaterial

Subjects: Engineering, Biomedical


Contributor: Francesco Lopresti, Vincenzo La Carrubba

Synthetic biopolymers are effective cues to replace damaged tissue in the tissue engineering (TE) field, both for in vitro and in vivo application. Among them, poly-L-lactic acid (PLLA) has been highlighted as a biomaterial with tunable mechanical properties and biodegradability that allows for the fabrication of porous scaffolds with different micro/nanostructures via various approaches. Tissue engineering applications of biomaterials have widely focused on studying synthetic polymers due to their interesting mechanical strength, elasticity, and biodegradability.

Keywords: poly-L-lactic acid (PLLA) ; tissue engineering ; Scaffold

## 1. Structure of PLLA

PLLA is a homopolymer of the PLA family, which also includes the homopolymer PDLA and the copolymer PDLLA (**Figure 1**)<sup>[1]</sup>. The attractive properties of this family have motivated researchers to focus their study on these polymers owing to their non-toxicity and excellent physical and mechanical properties<sup>[2]</sup>. Based on its compositional and structural properties, PLA is a thermoplastic aliphatic polyester. It may include stereochemical forms that give specific properties to materials. For instance, PLLA and PDLA are semicrystalline polymers, whereas PDLLA is usually amorphous<sup>[3]</sup>.



**Figure 1.** Enantiomeric forms of lactic acid<sup>[1]</sup>.

PLLA represents most PLA commercial grades. They are eco-friendly polymers obtained from 100% natural resources, such as cornstarch and sugar cane<sup>[4]</sup>. Its environmental advantage is linked both to the synthesis from non-petroleum-based processes (i.e., fermentation processes of oils, carbohydrates, or plants)<sup>[5]</sup> and the possibility of using eco-sustainable catalysts, such as cerium trichloride heptahydrate<sup>[6]</sup> and sorbitol<sup>[7]</sup>. PLLA production presents the advantage of lower energy use and, subsequently, lower costs<sup>[8]</sup>. PLLA is constituted by the cyclic dimer lactide LL- and has a crystalline structure between 30 and 40%<sup>[9]</sup> that can have several forms ( $\alpha$ ,  $\alpha'$ ,  $\beta$ , and  $\gamma$ ); the  $\alpha$  form is the most stable owing to its pseudo-orthorhombic unit cell, with the (10/3) chain adopting a helical conformation<sup>[4]</sup>. As a result, there is no symmetry on each side, leading to a distortion of the chain packing in the crystal lattice and energetical stability to the arranged chains<sup>[8]</sup>.

## 2. Biological Properties of PLLA

PLLA is an FDA-approved polymer known for its low toxicity compared to other synthetic polymers<sup>[1]</sup>. The anti-infective effects of PLLA had been established during in vivo and in vitro experiments, facilitating the repair of the infected tissue<sup>[5]</sup><sup>[10]</sup>. One of the significant advantages of PLLA with respect to other biopolymers relies on the performance of PLLA during implantation ensuring adequate mechanical properties for prolonged regenerative processes<sup>[11]</sup>. However, researchers have advised some doubts about the hydrophobic surface of this polymer that might compromise its biocompatibility since it affects the amount of absorbed proteins and the cell adhesion<sup>[12][13][14]</sup>.

Another crucial parameter that must be taken into account when determining the biological properties of one material is its biodegradation by-products that can cause local or systemic toxicity after implantation [11][15]. During PLLA degradation via hydrolysis, the polymer forms lactic acid as a by-product, typically present in the body and excreted as water and carbon dioxide [4]. The optimal degradation rate of a 3D support should match that of the ECM deposition of a specific tissue [16]. The kinetics of PLLA degradation depends on its crystallinity, strain, and microstructure that follows its deployment [17]. Lower crystallinity and higher strains lead to a faster degradation rate. PLLA is described as a resorbable synthetic polymer with slow degradation kinetics. This feature is given by the extra methyl group, leading to increased hydrophobicity and stability against hydrolysis [18]. The degradation time of PLLA is about 40 and 30 weeks in vitro [19] and in vivo [20], respectively.


### 3. Mechanical and Physical Properties of PLLA

PLLA is widely explored in tissue engineering applications because it is characterized by tunable mechanical properties [21]. Scaffolds fabricated from this bioresorbable material usually exhibit higher tensile strength (60–70 MPa) and modulus (2–4 GPa) but lower elongation at break (2–6%) compared to other synthetic polymers, such as PCL and PDLA [18]. High-strength tissues, such as bone [13], ligaments [22], and dermis [23], have been extensively investigated by PLLA-based scaffolds to provide physical support during tissue healing. However, the mechanical behavior of PLLA strongly depends on its molecular weight, crystallinity, and aging characteristics [24].

PLLA is a thermoplastic polymer with thermal plasticity and transparency [25]. The latter depends crucially on the crystal morphologies and crystallinity [26]. PLLA has a melting temperature ( $T_m$ ) between 170 and 180 °C and a glass transition temperature ( $T_g$ ) of about 60 °C.  $T_m$  may vary due to impurities [4]. Moreover, it is characterized by a mechanical strength of about 4.8 GPa, depending on its molecular weight [3][11]. Due to its polyorthoester trait, PLLA presents a hydrophobic nature allowing it to degrade while remaining structurally intact [27]. Thermal degradation strongly reduces the length of PLLA chains, leading to a decrease in the molecular weight and structural stability under thermal and mechanical stresses [28]. The  $\alpha$ -crystalline form of PLLA is the most thermodynamically stable owing to the C=O dipoles that are randomly oriented along the main chain, resulting in a non-polar form [29].

### 4. Reinforced PLLA-Based Biomaterials

Reinforcement additives that modify a polymeric material can act as a trigger for material degradation and can improve mechanical properties [4][30]. Reinforced PLLA structures offer a potential advantage to improve scaffold properties. Mariano et al. [10] obtained and characterized a PLLA-based nanocomposite reinforced with cellulose nanocrystals. According to their results, the presence of the filler increased the resistance of the melt flow and the Young's modulus value. Similarly,  $Mg(OH)_2$  was used to improve the mechanical properties of PLLA-based composites [25]. Another material that can be added to obtain high-performance PLLA-based material is  $BaTiO_3$ , which is specifically used to give piezoelectric properties to the polyester [31]. **Figure 2** shows the global and microscopic structure of PLLA fibers reinforced with  $BaTiO_3$  particles fabricated by Oh et al.




**Figure 2.** (d) Obtained as-spun PLLA fiber reinforced with  $BaTiO_3$  particles by the pilot-scale melt-spinning, and (e) FE-SEM image of the as-spun PLLA/ $BaTiO_3$  fibers.

Other additives have also been used to improve cell proliferation and protein absorption. Among them, chitosan [14] and hydroxyapatite [30] have been shown to enhance the osteoactivity of PLLA-based constructs. Moreover, PLLA was found to be itself a reinforcer for other materials. Natural polymers often used in the tissue engineering field lack good

mechanical properties. Collagen and gelatin sponges [32] and silk fibers [33] resulted in higher strength and elastic modulus when reinforced with PLLA.

## 5. Drug/Growth-Factor-Loaded PLLA Systems

Due to its relatively low biodegradation rate, PLLA is a suitable candidate for a prolonged drug delivery system [34]. In this regard, Sasaki et al. [35] developed a new drug-carrier material as blend particles composed of PLLA and rifampicin, an antibiotic drug used as an antibacterial and antifungal agent. The freeze-drying technique was used to prepare blend particles, starting from a solution composed of PLLA, rifampicin, and 1,4-dioxane. To avoid the heterogeneous adsorption method, the authors considered rifampicin suitable for their study because it is soluble in 1,4-dioxane, as well as PLLA. The obtained particles had an average porosity of  $92 \pm 3\%$  and a specific surface area of  $10\text{--}40\text{ m}^2\text{ g}^{-1}$  (Figure 3).



**Figure 3.** SEM images of the surface and interior of PLLA/rifampicin blend particles prepared by the drop freeze-drying method. (a) PLLA = 2.0 wt%, surface, (b) PLLA = 2.0 wt%, interior, (c) PLLA = 4.9 wt%, surface, and (d) PLLA = 4.9 wt%, interior.


The release kinetics of rifampicin in water were studied, resulting dependent on the morphology of the mixture particles that can be tuned by changing the concentration of the original solution and the freezing processing parameters.

Cao et al. evaluated the ability of the PLLA/polyhydroxybutyrate (PHB) for drug release [36]. They prepared the scaffold using solvent-free melt electrospinning and different concentrations of the drug dipyridamole (DPD). The authors found that DPD acts as a plasticizer for PLLA, thus allowing them to carry out the melting electrospinning process at a lower temperature if compared to neat PLLA. From their findings, the fibers containing DPD showed a rougher surface and nonuniform diameters within a single fiber than the fibers without DPD. The release profile of DPD was studied at different PLLA/PHB ratios (9/1 and 7/3) with the same drug concentration (1%), showing that the 9:1 PLLA/PHB system was more resistant to polymer hydrolysis than the 7:3 one. In line with this result, the rate of diffusion transport was approximately two times higher for the 7:3 PLLA/PHB fibers than for the 9:1 PLLA/PHB fibers. Overall, the authors proved the ability of this hybrid system to enhance sustained drug release.

In a more recent study, Guidotti et al. [37] developed a novel A-B-A triblock copolymer, based on PLLA as the A block, to prepare micro and nanoparticles for controlled drug delivery. Block B was a poly(butylene/triethylene succinate) P(BSTES) copolymer system in which the hydrophilic/hydrophobic ratio and hydrolytic degradation kinetics were adjusted for an adequate release of the drug by controlling the block length. To investigate the application of these new materials for manufacturing micro and nanoparticles for controlled drug delivery, the effect of both chemical structure and molecular architecture as well as of particles size was evaluated on drug release kinetics. Specifically, the authors loaded the micro and nanoparticles with dexamethasone, a synthetic corticosteroid with rapid gastrointestinal absorption. From their results, after observing the drug release from the copolymer and pure PLLA after 8 h of incubation under physiological conditions, the drug release from the copolymers was complete, while that from the PLLA matrix still continued, although more than 80% of the drug had already been released during incubation. The authors suggested that, in copolymer

microparticles, the drug was released through a diffusion-controlled mechanism. Instead, the release of the drug from the PLLA microparticles was also affected by the erosion process that occurs in the subsequent phases.

In the TE field, growth factors (GF) are a fundamental element since they have the potency to induce and enhance cellular responses [38][39]. According to Shen et al. [40], tissue regeneration with only cells and scaffolds is often unsuccessful, and exogenous growth factors must be in place to initiate the regeneration process. In this context, PLLA-base scaffolds incorporating growth factors were proposed to improve their biological activity and induce cell differentiation [41][39][42][43]. Yin et al. [44] fabricated silk fibroin/poly (L-lactide-ε-caprolactone) (SF/PLLA-CL) vascular graft loaded with platelet-rich growth factor (PRGF) by the electrospinning technique. PRGF was incorporated to promote effective smooth muscle cell (SMC) growth and infiltration into the graft. From their findings, SF/PLLA-CL/PRGF possessed a slightly higher strain (282%) and lower elastic modulus (1.8 MPa) than SF/PLLA-CL (259% and 2.5 MPa, respectively), showing appropriate mechanical properties compared to native blood vessels. Concerning the cellular behavior, PRGF enhanced cellular infiltration into the graft to a profound extent and induced fast SMC growth (**Figure 4**).



**Figure 4.** Confocal laser images of SMCs grown on SF/PLLA-CL/PRGF and SF/PLLA-CL for 1, 4, and 7 days.

In cartilage and bone TE, Zhang et al. [45] introduced poly(hydroxyethyl) methacrylate (PHEMA) blocks to conjugate GF-mimicking peptides on PLLA scaffold surface and fabricate a scaffold with improved bioactivity. Two different GF-mimicking peptides were separately conjugated, i.e., TGF-β1 and BMP-2 for inducing chondrogenic and osteogenic differentiation of BMSCs, respectively. These peptides were introduced into the PLLA scaffold after adjusting the density of acrylic groups in the copolymers during the molecular synthesis to conjugate more peptides. Based on the reported in vitro and in vivo tests, incorporating GF-mimicking peptides in PLLA–PHEMA scaffolds actively directed the stem cells along their respective differentiation pathways. They also promoted cartilage and mineralization compared to the control unconjugated scaffolds.

## References

1. Casalini, T.; Rossi, F.; Castrovinci, A.; Perale, G. A Perspective on Polylactic Acid-Based Polymers Use for Nanoparticles Synthesis and Applications. *Front. Bioeng. Biotechnol.* 2019, 7, 259.
2. Lopresti, F.; Carfi Pavia, F.; Vitrano, I.; Kersaudy-Kerhoas, M.; Brucato, V.; La Carrubba, V. Effect of hydroxyapatite concentration and size on morpho-mechanical properties of PLA-based randomly oriented and aligned electrospun nanofibrous mats. *J. Mech. Behav. Biomed. Mater.* 2020, 101, 103449.
3. Donate, R.; Monzón, M.; Alemán-Domínguez, M.E. Additive manufacturing of PLA-based scaffolds intended for bone regeneration and strategies to improve their biological properties. *e-Polymers* 2020, 20, 571–599.
4. Pandey, A.K.; Sakurai, S. Recent Developments in the Crystallization of PLLA-Based Blends, Block Copolymers, and Nanocomposites. In *Crystallization*; IntechOpen: Rijeka, Croatia, 2021.
5. Neumann, I.A.; Flores-Sahagun, T.H.S.; Ribeiro, A.M. Biodegradable poly (l-lactic acid) (PLLA) and PLLA-3-arm blend membranes: The use of PLLA-3-arm as a plasticizer. *Polym. Test.* 2017, 60, 84–93.



6. Pastore, G.; Gabrielli, S.; Cecchi, T.; Giuliani, A.; Cimarelli, C.; Menchi, A.; Marcantoni, E. A new and efficient lactic acid polymerization by multimetallic cerium complexes: A poly(lactic acid) suitable for biomedical applications. *RSC Adv.* 2021, 11, 10592–10598.
7. Teng, L.; Nie, W.; Zhou, Y.; Song, L.; Chen, P. Synthesis and characterization of star-shaped PLLA with sorbitol as core and its microspheres application in controlled drug release. *J. Appl. Polym. Sci.* 2015, 132, 42213–42219.
8. Tashiro, K.; Kouno, N.; Wang, H.; Tsuji, H. Crystal Structure of Poly(lactic acid) Stereocomplex: Random Packing Model of PDLA and PLLA Chains As Studied by X-ray Diffraction Analysis. *Macromolecules* 2017, 50, 8048–8065.
9. Sangroniz, A.; Chaos, A.; Iriarte, M.; Del Río, J.; Sarasua, J.R.; Etxeberria, A. Influence of the Rigid Amorphous Fraction and Crystallinity on Polylactide Transport Properties. *Macromolecules* 2018, 51, 3923–3931.
10. Mariano, M.; Pilate, F.; De Oliveira, F.B.; Khelifa, F.; Dubois, P.; Raquez, J.M.; Dufresne, A. Preparation of Cellulose Nanocrystal-Reinforced Poly(lactic acid) Nanocomposites through Noncovalent Modification with PLLA-Based Surfactants. *ACS Omega* 2017, 2, 2678–2688.
11. Basu, B. Three Dimensional Porous Scaffolds: Mechanical and Biocompatibility Properties. In *Biomaterials for Musculoskeletal Regeneration*; Springer: Singapore, 2017; pp. 353–384.
12. Ware, H.O.T.; Akar, B.; Sun, C.; Ameer, G. PLLA-infused citric acid-based bioresorbable vascular scaffolds 3D printed via microCLIP (Conference Presentation). In *Proceedings of the Emerging Digital Micromirror Device Based Systems and Applications XI*, San Francisco, CA, USA, 2–7 February 2019; p. 109320B.
13. Ju, J.; Peng, X.; Huang, K.; Li, L.; Liu, X.; Chitrakar, C.; Chang, L.; Gu, Z.; Kuang, T. High-performance porous PLLA-based scaffolds for bone tissue engineering: Preparation, characterization, and in vitro and in vivo evaluation. *Polymer* 2019, 180, 121707.
14. Lou, T.; Wang, X.; Yan, X.; Miao, Y.; Long, Y.Z.; Yin, H.L.; Sun, B.; Song, G. Fabrication and biocompatibility of poly(l-lactic acid) and chitosan composite scaffolds with hierarchical microstructures. *Mater. Sci. Eng. C* 2016, 64, 341–345.
15. Gregor, A.; Filová, E.; Novák, M.; Kronek, J.; Chlup, H.; Buzgo, M.; Blahnová, V.; Lukášová, V.; Bartoš, M.; Nečas, A.; et al. Designing of PLA scaffolds for bone tissue replacement fabricated by ordinary commercial 3D printer. *J. Biol. Eng.* 2017, 11, 31.
16. Eberli, D. *Tissue Engineering for Tissue and Organ Regeneration*; InTech: Rijeka, Croatia, 2011; ISBN 9789533076881.
17. Lin, S.; Dong, P.; Zhou, C.; Dallan, L.A.P.; Zimin, V.N.; Pereira, G.T.R.; Lee, J.; Gharaibeh, Y.; Wilson, D.L.; Bezerra, H. G.; et al. Degradation modeling of poly-L-lactide acid (PLLA) bioresorbable vascular scaffold within a coronary artery. *Nanotechnol. Rev.* 2020, 9, 1217–1226.
18. Ang, H.Y.; Huang, Y.Y.; Lim, S.T.; Wong, P.; Joner, M.; Foin, N. Mechanical behavior of polymer-based vs. metallic-based bioresorbable stents. *J. Thorac. Dis.* 2017, 9, S923–S934.
19. Qiu, T.; Zhao, L. Research into biodegradable polymeric stents: A review of experimental and modelling work. *Vessel Plus* 2018, 2, 12.
20. Woodard, L.N.; Grunlan, M.A. Hydrolytic Degradation and Erosion of Polyester Biomaterials. *ACS Macro Lett.* 2018, 7, 976–982.
21. Gorgani, S.; Zargar Kharazi, A.; Haghjooy Javanmard, S.; Rafiinia, M. Improvement of Endothelial Cell Performance in an Optimized Electrospun Pre-polyglycerol Sebacate-Poly Lactic Acid Scaffold for Reconstruction of Intima in Coronary Arteries. *J. Polym. Environ.* 2020, 28, 2352–2363.
22. Hochleitner, G.; Chen, F.; Blum, C.; Dalton, P.D.; Amsden, B.; Groll, J. Melt electrowriting below the critical translation speed to fabricate crimped elastomer scaffolds with non-linear extension behaviour mimicking that of ligaments and tendons. *Acta Biomater.* 2018, 72, 110–120.
23. Bacakova, L.; Zikmundova, M.; Pajorova, J.; Broz, A.; Filova, E.; Blanquer, A.; Matejka, R.; Stepanovska, J.; Mikes, P.; Jencova, V.; et al. Nanofibrous Scaffolds for Skin Tissue Engineering and Wound Healing Based on Synthetic Polymers. In *Applications of Nanobiotechnology*; Stoytcheva, M., Roumen, Z., Eds.; IntechOpen: London, UK, 2020; ISBN 978-1-78985-978-2.
24. Naseem, R.; Zhao, L.; Liu, Y.; Silberschmidt, V.V. Experimental and computational studies of poly-L-lactic acid for cardiovascular applications: Recent progress. *Mech. Adv. Mater. Mod. Process.* 2017, 3, 13.
25. Kang, E.Y.; Lih, E.; Kim, I.H.; Joung, Y.K.; Han, D.K. Effects of poly(L-lactide-ε-caprolactone) and magnesium hydroxide additives on physico-mechanical properties and degradation of poly(L-lactic acid). *Biomater. Res.* 2016, 20, 7.
26. Zhang, Y.; Li, F.; Yu, Q.; Ni, C.; Gu, X.; Li, Y.; You, J. Fabrication of PLLA with High Ductility and Transparency by Blending with Tiny Amount of PVDF and Compatibilizers. *Macromol. Mater. Eng.* 2019, 304, 1900316.

27. Patel, H.; Bonde, M.; Srinivasan, G. Biodegradable polymer scaffold for tissue engineering. *Trends Biomater Artif Organs* 2011, 25, 20–29.
28. Melo, P.; Naseem, R.; Corvaglia, I.; Montalbano, G.; Pontremoli, C.; Azevedo, A.; Quadros, P.; Gentile, P.; Ferreira, A. M.; Dalgarno, K.; et al. Processing of Sr<sup>2+</sup> containing PLLA-based hybrid composites for additive manufacturing of bone scaffolds. *Front. Mat.* 2020, 7, 413.
29. Sultana, A.; Ghosh, S.K.; Sencadas, V.; Zheng, T.; Higgins, M.J.; Middya, T.R.; Mandal, D. Human skin interactive self-powered wearable piezoelectric bio-e-skin by electrospun poly-L-lactic acid nanofibers for non-invasive physiological signal monitoring. *J. Mater. Chem. B* 2017, 5, 7352–7359.
30. Ciapetti, G.; Granchi, D.; Devescovi, V.; Baglio, S.R.; Leonardi, E.; Martini, E.; Jurado, M.J.; Olalde, B.; Armentano, I.; Kenny, J.M.; et al. Enhancing osteoconduction of PLLA-based nanocomposite scaffolds for bone regeneration using different biomimetic signals to MSCs. *Int. J. Mol. Sci.* 2012, 13, 2439–2458.
31. Oh, H.J.; Kim, D.K.; Choi, Y.C.; Lim, S.J.; Jeong, J.B.; Ko, J.H.; Hahm, W.G.; Kim, S.W.; Lee, Y.; Kim, H.; et al. Fabrication of piezoelectric poly(L-lactic acid)/BaTiO<sub>3</sub> fibre by the melt-spinning process. *Sci. Rep.* 2020, 10, 16339.
32. Lu, H.; Oh, H.H.; Kawazoe, N.; Yamagishi, K.; Chen, G. PLLA-collagen and PLLA-gelatin hybrid scaffolds with funnel-like porous structure for skin tissue engineering. *STAdM* 2012, 13, 064210.
33. Zeng, Y.; Li, X.; Liu, X.; Yang, Y.; Zhou, Z.; Fan, J.; Jiang, H. PLLA Porous Microsphere-Reinforced Silk-Based Scaffolds for Auricular Cartilage Regeneration. *ACS Omega* 2021, 6, 3372–3383.
34. Ramesh, B.; Cherian, K.M.; Fakoya, A.O.J. Fabrication and Electrospinning of 3D Biodegradable Poly-L-Lactic Acid (PLLA) Nanofibers for Clinical Application. *Methods Mol. Biol.* 2020, 2125, 119–128.
35. Sasaki, T.; Matsuura, H.; Tanaka, K. Preparation and Drug-Release Kinetics of Porous Poly(L-lactic acid)/Rifampicin Blend Particles. *ISRN Polym. Sci.* 2014, 128154.
36. Cao, K.; Liu, Y.; Olkhov, A.A.; Siracusa, V.; Iordanskii, A.L. PLLA-PHB fiber membranes obtained by solvent-free electrospinning for short-time drug delivery. *Drug Deliv. Transl. Res.* 2018, 8, 291–302.
37. Guidotti, G.; Soccio, M.; Gazzano, M.; Salatelli, E.; Lotti, N.; Munari, A. Micro/nanoparticles fabricated with triblock PLLA-based copolymers containing PEG-like subunit for controlled drug release: Effect of chemical structure and molecular architecture on drug release profile. *Polym. Degrad. Stab.* 2020, 180, 109306.
38. Bisht, B.; Hope, A.; Mukherjee, A.; Paul, M.K. Advances in the Fabrication of Scaffold and 3D Printing of Biomimetic Bone Graft. *Ann. Biomed. Eng.* 2021, 49, 1129–1150.
39. Kim, S.; Lee, J.; Hwang, M.P.; Wang, Y.; Kim, K. Influence of fiber architecture and growth factor formulation on osteoblastic differentiation of mesenchymal stem cells in coacervate-coated electrospun fibrous scaffolds. *J. Ind. Eng. Chem.* 2019, 79, 236–244.
40. Shen, H.; Hu, X. Growth factor loading on aliphatic polyester scaffolds. *RSC Adv.* 2021, 11, 6735–6747.
41. Choi, J.W.; Kim, Y.S.; Park, J.K.; Song, E.H.; Park, J.H.; Kim, M.S.; Shin, Y.S.; Kim, C.H. Controlled Release of Hepatocyte Growth Factor from MPEG-b-(PCL-ran-PLLA) Diblock Copolymer for Improved Vocal Fold Regeneration. *Macromol. Biosci.* 2017, 17, 1600163.
42. Liu, Y.; Nelson, T.; Cromeens, B.; Rager, T.; Lannutti, J.; Johnson, J.; Besner, G.E. HB-EGF embedded in PGA/PLLA scaffolds via subcritical CO<sub>2</sub> augments the production of tissue engineered intestine. *Biomaterials* 2016, 103, 150–159.
43. Zhang, K.; Huang, D.; Yan, Z.; Wang, C. Heparin/collagen encapsulating nerve growth factor multilayers coated aligned PLLA nanofibrous scaffolds for nerve tissue engineering. *J. Biomed. Mater. Res.—Part A* 2017, 105, 1900–1910.
44. Yin, A.; Bowlin, G.L.; Luo, R.; Zhang, X.; Wang, Y.; Mo, X. Electrospun silk fibroin/poly(L-lactide-ε-caplacton) graft with platelet-rich growth factor for inducing smooth muscle cell growth and infiltration. *Regen. Biomater.* 2016, 3, 239–245.
45. Zhang, Z.; Gupte, M.J.; Jin, X.; Ma, P.X. Injectable peptide decorated functional nanofibrous hollow microspheres to direct stem cell differentiation and tissue regeneration. *Adv. Funct. Mater.* 2015, 25, 350–360.